Cyclin-Dependent Kinases
Cyclin-dependent kinases is a group of serine/threonine kinases. It is activated by binding to cyclin and participates in the regulation of cell cycle.
Products Related to Cyclin-Dependent Kinases(70)
- GC13690BS-181 HClCAS: 1397219-81-6Purity: >99.00%
BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.
- GC14294Cdk1/2 Inhibitor IIICAS: 443798-47-8Purity: >98.50%
Cdk1/2 Inhibitor III is a potent CDK1 and CDK2 inhibitor with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. Cdk1/2 Inhibitor III is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC50s of 8.9 nM and 29.2 nM, respectively.
- GC15173PD 0332991 (Palbociclib)CAS: 571190-30-2Purity: >99.50%
PD 0332991 (Palbociclib) (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. PD 0332991 (Palbociclib) has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
- GC15215Iso-OlomoucineCAS: 101622-50-8Purity: >98.00%
inactive stereoisomer of the Cdk5 inhibitor olomoucine
- GC15421Palbociclib (PD0332991) IsethionateCAS: 827022-33-3Purity: >98.00%
Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib (PD0332991) Isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
- GC15588PHA-848125CAS: 802539-81-7Purity: >99.50%
PHA-848125 (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC13649 | Arcyriaflavin A | 118458-54-1 | >98% | |
cdk4/cyclin D1 inhibitor | ||||
| GC13690 | BS-181 HCl | 1397219-81-6 | >99.00% | |
BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9. | ||||
| GC13998 | AT7519 Hydrochloride | 902135-91-5 | >99.00% | |
A Cdk inhibitor | ||||
| GC14002 | Bohemine | 189232-42-6 | >98.00% | |
CDK inhibitor | ||||
| GC14182 | Kenpaullone | 142273-20-9 | >98.00% | |
CDK1/cyclin B and GSK-3β inhibitor | ||||
| GC14230 | K03861 | 853299-07-7 | >98.00% | |
K03861 (K03861) is a type II CDK2 inhibitor with Kd of 8.2 nM. K03861 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins. | ||||
| GC14294 | Cdk1/2 Inhibitor III | 443798-47-8 | >98.50% | |
Cdk1/2 Inhibitor III is a potent CDK1 and CDK2 inhibitor with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. Cdk1/2 Inhibitor III is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC50s of 8.9 nM and 29.2 nM, respectively. | ||||
| GC14650 | CGP60474 | 164658-13-3 | >98.00% | |
A CDK inhibitor | ||||
| GC14707 | Purvalanol A | 212844-53-6 | >99.00% | |
potent, and cell-permeable CDK inhibitor | ||||
| GC15047 | PHA-793887 | 718630-59-2 | >98.00% | |
Pan-Cdk inhibitor | ||||
| GC15173 | PD 0332991 (Palbociclib) | 571190-30-2 | >99.50% | |
PD 0332991 (Palbociclib) (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. PD 0332991 (Palbociclib) has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma. | ||||
| GC15215 | Iso-Olomoucine | 101622-50-8 | >98.00% | |
inactive stereoisomer of the Cdk5 inhibitor olomoucine | ||||
| GC15421 | Palbociclib (PD0332991) Isethionate | 827022-33-3 | >98.00% | |
Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib (PD0332991) Isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma. | ||||
| GC15571 | SU 9516 | 377090-84-1 | >99.50% | |
A pro-apoptotic Cdk2/cyclin A inhibitor | ||||
| GC15588 | PHA-848125 | 802539-81-7 | >99.50% | |
PHA-848125 (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively. | ||||
| GC15597 | AT7519 trifluoroacetate | 1431697-85-6 | >98.00% | |
| GC15607 | ON123300 | 1357470-29-1 | >99.00% | |
multi-targeted kinase inhibitor,inhibits CDK4, Ark5, PDGFRβ, FGFR1, RET, and Fyn | ||||
| GC15841 | Alsterpaullone | 237430-03-4 | >98.00% | |
CDKs and GSK3β inhibitor | ||||
| GC15870 | AT7519 | 844442-38-2 | >99.50% | |
Multi-CDK inhibitor | ||||
| GC16063 | Flavopiridol | 146426-40-6 | >98.00% | |
An inhibitor of cyclin-dependent kinases | ||||
| GC16268 | Purvalanol B | 212844-54-7 | >98.50% | |
CDK1/CDK2/CDK4 inhibitor | ||||
| GC16413 | TMCB | 905105-89-7 | >98.00% | |
CK2 and ERK8 inhibitor | ||||
| GC16420 | THZ531 | 1702809-17-3 | >98.00% | |
CDK12 and CDK13 covalent inhibitor | ||||
| GC16425 | Flavopiridol hydrochloride | 131740-09-5 | >98.00% | |
CDK inhibitor, potent and selective | ||||